Atosiban

Chemical formula: C₄₃H₆₇N₁₁O₁₂S₂  Molecular mass: 994.19 g/mol  PubChem compound: 5311010

Therapeutic indications

Atosiban is indicated for:

Pre-term birth

Population group: women, only adults (18 - 65 years old)

Atosiban is indicated to delay imminent pre-term birth in pregnant women with:

  • regular uterine contractions of at least 30 seconds duration at a rate of ≥4 per 30 minutes
  • a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥50%
  • age ≥18 years
  • a gestational age from 24 until 33 completed weeks
  • a normal fetal heart rate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Atosiban is contraindicated in the following cases:

Premature rupture of the membranes >30 weeks of gestation

PPROM - Preterm premature rupture of membranes

Abnormal foetal heart rate

Abnormal fetal heart rate

Antepartum uterine haemorrhage requiring immediate delivery

Antepartum hemorrhage

Eclampsia, severe pre-eclampsia requiring delivery

at least one of
Eclampsia
Severe pre-eclampsia

Intrauterine foetal death

Fetal death

Suspected intrauterine infection

Infection of uterus

Placenta praevia

Placenta previa

Abruptio placenta

Placental abruption

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: TRACTOCILE Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈